Bioavailabilityof DFN-15 at 3 Different Doses Versus Comparator to Determine Dose-proportionality of DFN-15 in Healthy Volunteers Under Fasting Conditions

Trial Profile

Bioavailabilityof DFN-15 at 3 Different Doses Versus Comparator to Determine Dose-proportionality of DFN-15 in Healthy Volunteers Under Fasting Conditions

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs DFN 15 (Primary) ; Celecoxib
  • Indications Migraine
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Dr Reddys Laboratories
  • Most Recent Events

    • 26 Jul 2017 Primary endpoint (Maximum Plasma Concentration (Cmax) of DFN-15) has been met as per the results published in the Clinical Drug Investigation
    • 26 Jul 2017 Primary endpoint (Area Under the Curve (AUC) [0-inf] of DFN-15) has been met as per the results published in the Clinical Drug Investigation
    • 26 Jul 2017 Results published in the Clinical Drug Investigation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top